Article Highlights:
-
A new phase 2b clinical trial of tirasemtiv (formerly CK-2017357) in people with amyotrophic lateral sclerosis (ALS) is set to launch in late 2012.
-
The new phase trial is designed to evaluate the safety, tolerability and efficacy (how well the therapy works) of tirasemtiv in people with ALS.
-
Investigators will measure trial participants’
pulmonary, respiratory and skeletal muscle function.
-
Tirasemtiv is thought to increase the sensitivity of muscle fibers to calcium, resulting in a potential increase in muscle force generation.
See more info here
No comments:
Post a Comment